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Type 2 diabetes mellitus is a chronic progressive disease typified by a loss of glycaemic control over 
time as the insulin secreting pancreatic -cells lose their ability to compensate for the prevailing levels 
of insulin sensitivity. Several abnormalities are associated with diabetes and metabolic syndrome. 
Butyrylcholinesterase activity in diabetes and metabolic syndrome is generally under reported.  Blood 
samples and demographic data were obtained from one hundred and five patients presenting at 
Specialist Hospital Sokoto, Nigeria. These were screened for type 2 diabetes according to the 
guidelines of the American Diabetes Association. Based on anthropometric indices and clinical data, 
patients were stratified into to 4 groups: Control (n = 44), type 2 diabetics with metabolic syndrome (n = 
14), obese type 2 diabetics without metabolic syndrome (n = 21) and non-obese type 2 diabetics without 
metabolic syndrome (n = 26). Butyrylcholinesterase was assayed by kinetic and colorimetric method, 
other biochemical and clinical parameters were according to standard methods. Type 2 diabetics with 
or without metabolic syndrome have significantly higher activity of butyrylcholinesterase than control 
group. The higher activity of the enzyme may have been influenced by hyperglycemia, obesity and 
metabolic syndrome through enhanced transcription or catalytic mechanism of the enzyme or both. 
Butyrylcholinesterase activity may serve as marker to predict the development of type 2 diabetes and or 
metabolic syndrome.  
 





Type 2 diabetes mellitus is a chronic progressive disease 
typified by a loss of glycaemic control over time as the 
insulin secreting pancreatic -cells lose their ability to 
compensate for the prevailing levels of insulin sensitivity. 
The hyperglycemia of type 2 diabetes is associated with 
an increased risk of micro vascular (retinopathy, neuro-
pathy, nephropathy) and macro vascular (myocardiac 
infarction, stroke) events (Home, 2005; Stettler et al., 
2006). Diabetes (together with obesity) represents a 
serious threat to the health of the populations of almost 
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estimates that 1.1 million people died of diabetes in 2005 
(Nath et al., 2006). Although viewed as a gross under-
estimate (Nath et al., 2006), the figure is expected to rise 
by 50% during the next ten years (Amos et al., 1997; 
A.D.A. 2008). Metabolic syndrome is a complex condition 
associated with obesity, and characterized by a cluster of 
closely related clinical features such as dyslipidaemia, 
inflammation, insulin resistance or full blown diabetes and 
hypertension (Reaven, 1989). A meta- analysis of pros-
pective studies has shown that presence of metabolic 
syndrome increases the risk of type 2 diabetes (Bakori et 
al., 1999). The prevalence of diabetes mellitus in Nigeria 
is reported to be one to four percent (Bakori et al., 1999; 
Akinkugbe, 2000) but that of metabolic syndrome has not 
been reported. 
Butyrylcholinesterase (E.C. 3.1.1.8) (BuChE) is primarily 
associated with glial cells, endothelial cells and neurons 
(Darvesh, 2003). Its activity in healthy human brain is low 
compared with acetyl cholinesterase although it may 
likely have been underestimated (Li et al., 2000). BuChE,  
















Non Obese, Non Diabetes (M.S absent)- Control 44 50 ±12 26 18 23 ± 4 83 ± 10 110 ± 5 70 ± 5 
Obese type 2 Diabetes (M.S present) 14 56 ± 8 9 5 40 ± 3* 105 ± 11* 145 ± 5* 85 ± 5 * 
Obese type 2 Diabetes (M.S absent)  21 56 ± 8 14 7 32 ± 2* 103 ± 8* 125 ± 5* 75 ±5* 
Non-Obese type 2 Diabetes (M.S absent) 26 54 ± 9 19 7 22 ± 4 86 ± 10ns 120 ± 5 * 60 ± 5ns 
 
N = Number of subjects; M = male; F = female; BMI = body mass index, W.C. = waist circumference; *, significantly different compared with control at 




although discovered since 1932 (Stedman et al., 1932), 
its physiologic importance has been poorly understood.  
But the enzyme is thought to play a key role in com-
pensating for the action of acetyl cholinesterase (Mesulam 
et al., 2002), a widespread group of enzymes present in 
both cholinergic and non-cholinergic tissues as well as in 
plasma (Randell et al., 2005). There is an urgent need for 
new approaches to address type 2 diabetes and its 
associated complications. In particular, understanding the 
various processes that result in the disease and 
dysfunction of molecular mechanisms will pave the way 
for the development of new treatment strategies (Nath et 
al., 2006). Although activities of BuChE have been 
reported in in vitro and animal models (Whittaker,1986; 
Darvesh, 2003), studies on human diabetics and 
metabolic syndrome have not been widely reported 
(Calderon-Margalit et al., 2006). We therefore report our 
findings of abnormally high activity of BuChE in a cohort 
of Nigerians with type 2 diabetes with and without 
metabolic syndrome.  
 
 
MATERIALS AND METHODS 
 
Subjects and study design 
 
Blood samples and demographic data were obtained from subjects 
presenting as out-patients at the Diabetic Clinic of the Specialist 
Hospital, Sokoto, Nigeria, after obtaining institutional approval and 
study participants submitting signed consent forms. The subjects 
were screened for diabetes type 2 according to the guidelines of 
American Diabetes Association (A.D.A 2003). A total number of 105 
subjects were enrolled into the study. 
 
 
Sample collection and preparations 
 
The study was conducted from April to July 2008. Three milliliters 
(mls) of fasting veinous blood samples were collected from the 
subjects at the Chemical Pathology Laboratory of the same 
hospital. Prior to blood collection, anthropometric and clinical data 
were collected and recorded. Blood pressure was measured with 
aneroid mercury sphygmomanometer (Accoson) using the non 
dominant arm and after ten minutes of rest. Patients were defined 
as hypertensive if they have blood pressure > 140 systolic/90 
diastolic mmHg. Anthropometric indices including weight, height, 
waist and hip circumferences were measured with patients wearing 
light clothing and no shoes on. Body mass index (BMI), was 
calculated as ratio of weight (kg) divided by the square of the height 
(m2). Weight status was classified using BMI into the following 
categories: normal, (18.5 - 24.9 kg/m2), overweight (25 - 29.9 
kg/m2) and obesity (>30) (W.H.O. 1997). Waist circumference 
greater than 102 cm (male) or greater than 88 cm (female) was 
taken to be abdominal obesity. 
Samples for biochemistry analyses were centrifuged at 3000 g 
for five minutes within thirty minutes of collection. The serum was 
extracted and batch analyzed immediately using Technicon SMAC 
(Technicon Instruments Corporation) for triglycerides (using 
enzymatic method), high density lipoprotein cholesterol (HDL-C) 
using modified enzymatic method of precipitating low density 
lipoprotein (LDL) and very low density lipoprotein (VLDL) with 
dextran magnesium sulfate, blood glucose using glucose oxidase 
method (Trinder, 1969) and plasma BuChE using kinetic 
colorimetric method employing S-butyryl-thiocholiniiodide (Sigma 
Chemical Co. M.A.) as substrate. Samples not analyzed immediately 
(except for glucose which was determined immediately) were stored 
in plain tubes at 2 - 8°C. Based on the lipid profiles and anthro-
pometric indices, patients were allocated to groups. Group 1 (n = 
44; 26 males and 18 females) served as control. Group II  (n = 14; 9 
males and 5 females) obese type 2 diabetics with metabolic 
syndrome characterized by fasting blood glucose level above 7 
mmol/l, HDL-Cholesterol <1.0 mmol/L, blood pressure > 140/90 
mmHg systolic/diastolic , triglyceride >1.7 mmol/L and waist circum-
ference > 102 cm (male) or 88 cm (female). Group III (n = 21; 14 
males and 7 females) characterized by obesity, type 2 diabetes 
without metabolic syndrome and Group IV (n = 26; 19 males and 7 
females) non-obese, type 2 diabetic subjects without metabolic 





Data are presented as mean ± standard deviation. Differences 
between group means and control group mean were tested using 
student’s t-test for two group comparisons and P values less than 
0.05 were regarded as statistically significant. Statistical analyses 
were performed using Graph Pad Instat (Graph Pad Software, San 





The anthropometric and clinical data of the study subjects 
are presented in Table 1. The mean ages of the subjects 
in all the Groups (I - IV) were not statistically significant 
(P>0.05) but the control group had lower mean ages (50 
± 12years) followed by Group IV (54 ± 9years) then 
Group II and III (56 ± 8years), respectively. The 
difference in the BMI of group  II  (40 ± 3 Kg/m2)  and  the  




Table 2. Biochemical data of type 2 diabetics and control subjects in Sokoto, Nigeria. 
 
Groups TG (mmol/L) HDL-C (mmol/L) FBG (mmol/L) BuChE (IU/L) 
I 1.69 ± 0.18 2.17 ± 0.23 5.20 ± 0.87 2.7± 0.3 * 
II 5.90 ± 0.71* 0.58 ± 0.11 * 13.50 ± 4.00 * 8.9 ± 0.3* 
III 1.47 ± 0.39 1.44 ± 0.32 * 11.6 ± 3.3 * 8.2 ± 0.2* 
IV 2.26 ± 0.39 * 1.12 ± 0.37 * 13.80 ± 4.60 * 8.6 ± 0.3 * 
 
M.S = Metabolic syndrome; TG = triglyceride, HDL-C = high density lipoprotein-cholesterol, FBG = 
fasting blood glucose; BuChE = butyrylcholinesterase; *, statistically significant when compared to the 
control group at P<0.05; Group I, Non-obese, non diabetes (M.S absent)-control ; Group II, Obese type 
2 Diabetes (M.S present); Group III, Obese type 2 Diabetes (M.S absent) ; Group IV, Non-obese type 2  




control group - Group I (23 ± 4 Kg/m2) and that of Group 
III (32± 2 kg/m2) and the control group were statistically 
significant (P< 0.05). The difference in the BMI of Group 
IV (22 ± 4 kg/m2) and Group I (23 ± 4 Kg/m2) were not 
statistically significant (P> 0.05). Group II had higher 
mean BMI (40 ± 3 kg/m2) followed by Group III (32 ± 2 
kg/m2). The differences in the mean waist circumference 
between Group II and I and Group III and I were statistically 
significant (P<0.05). The difference in the mean waist 
circumference of Group IV and I was not statistically 
significant (P>0.05). Group II had higher mean waist 
circumference followed by Group III (103 ± 8 cm), then 
Group IV. 
The difference in the mean blood pressure of Group II 
(145/85 ± 5 mm) and that of Group I (110/70 ± 5 mmHg) 
and Group III (125/75 ± 5 mmHg) and Group I were 
statistically significant (P<0.05). The difference in the BMI 
of group IV (22±4kg/m2) and group I (23±4 Kg/m2) was 
not statistically significant (P> 0.05). The biochemical 
data of the study subjects are presented in Table 2. The 
differences in the mean triglyceride level of Group II (5.90 
± 0.71 mmo1/L) and Group I (1.69 ± 0.18 mmol/L) and 
that of Group IV (2.26+0.39 mmol/L) were statistically 
significant (P<0.05), that of Group III (1.47 ± 0.39 
mmo1/L) and Group I (1.69 ± 0.18 mmo1/L) was not 
statistically significant (P>0.05). There exists a statistically 
significant difference in the mean HDL-cholesterol level 
between Group II (0.58 ± 0.11), III (1.44 ± 0.32 mmo1/L), 
IV (1.12 ± 0.37 mmo1/L) and I (2.17 ± 0.23 mmo1/L). The 
differences in the mean fasting blood glucose level of 
Group II (13.50 ± 4.00 mmo1/L), III (11.6 ± 3.30 
mmoi1/L), IV (13.80 ± 460 mmo1/L) and that of  Group I 
were also statistically significant (P<0.05). Group I 
showed a significantly lower activity of BuChE (2714 ± 
332 IU/L) compared to all other groups. Comparing Group II 
and III, there exists a statistically significant difference in 
the activity of the enzyme although they were both obese 
type 2 diabetics. The difference in the mean activity of the 
enzyme between Group III (8169 ± 278 IU/L) and Group 
IV (8642 ± 315 IU/L) was also statistically significant, 
although they were both type 2 diabetics and devoid of 
metabolic syndrome. There is also a statistically significant 
difference in the  mean  activity  of  the  enzyme  between  





The present cross sectional study of middle-aged and 
elderly Nigerian subjects with type 2 diabetes with and 
without metabolic syndrome is to the best of our 
knowledge the first to report the activity of BuChE in a 
community-based sample. Several Nigerian (Sokoto - 
based) studies have reported on the demographic and 
clinical correlates of metabolic syndrome in type 2 
diabetics. From the studies by Isezuo et al. (2003) and 
Isezuo and Ezunu (2005), incidence of full blown metabolic 
syndrome was 20.5% in 52 patients, about 72.4% were 
dyslipidaemic, and 54.3% were hypertensive. Concurrent 
hypertension and dyslipidaemia, obesity and dyslipidaemia, 
and hypertension and obesity occurred in 44.4, 42. 5 and 
33.1% of type 2 diabetes, respectively. The connection 
between type 2 diabetes and dyslipidaemia in humans 
has been well recognized and reported from other 
countries (Astrup and Finer, 2000; Abbasi et al., 2002) 
and its link with mortality (Calderon-Margalit et al., 2006). 
Metabolic syndrome is found to be common in diabetic 
population. Its presence is associated with high levels of 
plasma butyrylcholinesterase activity. From the results of 
this study, Group II only fulfilled the diagnostic criteria for 
metabolic syndrome. According to World Health 
Organization standard criteria, a person must have 
fulfilled three or more of the following criteria to be 
classified as having metabolic syndrome: increased waist 
circumference with population specific cut off values, 
increased triacylglycerol levels, low HDL-cholesterol 
concentration, elevated blood pressure or hypertension 
and elevated glucose concentration or treatment with a 
hypoglycaemic agent. It has been observed that these 
criteria have not been validated for their ability to 
discriminate optimally for individuals with both metabolic 
syndrome and related increase in cardiovascular disease 
(CVD) risk particularly critical for assessment of CVD risk 
associated with excess visceral adiposity in non-
Caucasian populations. Much work is needed in this area 





although are obese and have type 2 diabetes, did not 
satisfy the above criteria. Group IV subjects were type 2 
diabetic, not obese and did not have the metabolic 
syndrome. This finding corroborates the findings from 
other reports (Isezuo et al., 2003; Isezuo and Ezunu, 
2005) that the incidence of metabolic syndrome increases 
or correlates more closely with abdominal obesity. 
Plasma BuChE activity is significantly higher in all 
subjects with type 2 diabetes whether or not metabolic 
syndrome is present. Abbot et al. (1993) have reported 
similar finding. The activity of BuChE could serve as a 
marker for type 2 diabetes (Sridhar and Nirmala, 2002; 
Randell et al., 2005). However, its relevance as a marker 
for metabolic syndrome is equivocal since high activity 
occurs both in patients with metabolic syndrome and 
those without it but are equally obese. Measurement of 
the patients plasma BuChE level could be incorporated 
as a routine mass screening programme for type 2 
diabetes and metabolic syndrome in the community. 
There is an urgent need for new approaches to address 
obesity and type 2 diabetes and their associated compli-
cations (Nath et al., 2006). In particular, understanding 
the various processes that give rise to the characteristics 
of metabolic syndrome and its attendant risks-from 
abnormal regulation of energy metabolism through to 
dysfunction of molecular mechanism (Nath et al., 2006) 
thus paving the way for the development of new 
treatment strategies. 
Patients with type 2 diabetes and metabolic syndrome 
exhibit higher levels of plasma butyrylcholinesterase and 
higher scores of anthropometric indices. The higher 
activity of the enzyme may have been influenced by 
hyperglycemia, obesity and metabolic syndrome through 
enhanced transcription or catalytic mechanism of the 
enzyme. Butyrylcholinesterase activity may serve as a 
marker to predict the development of type 2 diabetes and 
or metabolic syndrome. A question worth asking is what 
is the molecular basis of the increased activity of the 
enzyme in type 2 diabetes? Butyrylcholinesterase K variant 
allele is more common among type 2 diabetics than in 
non-diabetic subjects suggesting a close association 
between the butyrylcholinesterase gene (3q26) and the 
disease which could be related to an identified 
susceptibility locus on chromosome position 3q27 but 
independent of islet function (Hashim et al., 2001). 
Further studies show the positive correlation between 
activity of the enzyme and risk factors for coronary heart 
disease such as Apo B , triglycerides and diabetes (Hashim 
et al., 2001), hence the association between increased 
activity of the enzyme, lipoprotein synthesis, hypertension 
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